Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000950170-25-093430
Filing Date
2025-07-02
Accepted
2025-07-02 19:41:56
Documents
2
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 4 ownership.html 4  
1 4 ownership.xml 4 3812
2 EX-24 ikt-ex24.htm EX-24 15998
  Complete submission text file 0000950170-25-093430.txt   21271
Mailing Address 1000 N. WEST STREET, SUITE 1200 WILMINGTON DE 19801
Business Address 1000 N. WEST STREET, SUITE 1200 WILMINGTON DE 19801 (302) 295-3800
Inhibikase Therapeutics, Inc. (Issuer) CIK: 0001750149 (see all company filings)

EIN.: 263407249 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O RAYZEBIO, INC. 5505 MOREHOUSE DRIVE, SUITE 300 SAN DIEGO CA 92121
Business Address
Kush Arvind (Reporting) CIK: 0001986806 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39676 | Film No.: 251103362